Repligen (NASDAQ:RGEN) Updates FY 2025 Earnings Guidance

Repligen (NASDAQ:RGEN) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided earnings per share guidance of 1.670-1.760 for the period, compared to the consensus earnings per share estimate of 1.710. The company issued revenue guidance of $685.0 million-$710.0 million, compared to the consensus revenue estimate of $692.8 million.

Repligen Price Performance

Shares of NASDAQ RGEN traded down $5.58 during trading on Friday, hitting $157.09. The company had a trading volume of 211,965 shares, compared to its average volume of 591,497. The firm has a market capitalization of $8.80 billion, a price-to-earnings ratio of -424.53, a price-to-earnings-growth ratio of 4.23 and a beta of 0.99. Repligen has a fifty-two week low of $113.50 and a fifty-two week high of $203.13. The stock has a fifty day simple moving average of $155.17 and a two-hundred day simple moving average of $148.81. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, topping analysts’ consensus estimates of $0.41 by $0.03. The firm had revenue of $167.55 million for the quarter, compared to analyst estimates of $167.58 million. Repligen had a negative net margin of 3.36% and a positive return on equity of 3.90%. On average, research analysts expect that Repligen will post 1.54 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the stock. HC Wainwright restated a “buy” rating and set a $180.00 price target on shares of Repligen in a research report on Friday. TD Cowen assumed coverage on shares of Repligen in a research report on Monday, February 10th. They set a “buy” rating and a $200.00 price target on the stock. Canaccord Genuity Group assumed coverage on shares of Repligen in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. Wolfe Research assumed coverage on shares of Repligen in a research note on Thursday, November 14th. They set a “peer perform” rating on the stock. Finally, Canaccord Genuity Group lifted their target price on shares of Repligen from $165.00 to $170.00 and gave the stock a “hold” rating in a research note on Friday. Six investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, Repligen has a consensus rating of “Moderate Buy” and a consensus target price of $183.36.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.